Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 1
1999 1
2000 1
2001 2
2002 1
2004 1
2005 1
2006 1
2007 4
2008 5
2009 1
2010 2
2011 6
2012 10
2013 4
2014 1
2015 10
2016 10
2017 13
2018 18
2019 23
2020 18
2021 12
2022 9
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Results by year

Filters applied: . Clear all
Page 1
Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update.
Eyvazi S, Farajnia S, Dastmalchi S, Kanipour F, Zarredar H, Bandehpour M. Eyvazi S, et al. Among authors: dastmalchi s. Curr Cancer Drug Targets. 2018;18(9):857-868. doi: 10.2174/1568009618666180102102311. Curr Cancer Drug Targets. 2018. PMID: 29295696 Review.
Current trends in development of HDAC-based chemotherapeutics.
Cheshmazar N, Hamzeh-Mivehroud M, Nozad Charoudeh H, Hemmati S, Melesina J, Dastmalchi S. Cheshmazar N, et al. Among authors: dastmalchi s. Life Sci. 2022 Nov 1;308:120946. doi: 10.1016/j.lfs.2022.120946. Epub 2022 Sep 10. Life Sci. 2022. PMID: 36096240 Review.
Histamine H3 receptor antagonists/inverse agonists: Where do they go?
Ghamari N, Zarei O, Arias-Montaño JA, Reiner D, Dastmalchi S, Stark H, Hamzeh-Mivehroud M. Ghamari N, et al. Among authors: dastmalchi s. Pharmacol Ther. 2019 Aug;200:69-84. doi: 10.1016/j.pharmthera.2019.04.007. Epub 2019 Apr 24. Pharmacol Ther. 2019. PMID: 31028835 Review.
AMPK: A promising molecular target for combating cisplatin toxicities.
Rashtchizadeh N, Argani H, Ghorbanihaghjo A, Sanajou D, Hosseini V, Dastmalchi S, Nazari Soltan Ahmad S. Rashtchizadeh N, et al. Among authors: dastmalchi s. Biochem Pharmacol. 2019 May;163:94-100. doi: 10.1016/j.bcp.2019.02.006. Epub 2019 Feb 7. Biochem Pharmacol. 2019. PMID: 30738797 Review.
Overview of CD24 as a new molecular marker in ovarian cancer.
Tarhriz V, Bandehpour M, Dastmalchi S, Ouladsahebmadarek E, Zarredar H, Eyvazi S. Tarhriz V, et al. Among authors: dastmalchi s. J Cell Physiol. 2019 Mar;234(3):2134-2142. doi: 10.1002/jcp.27581. Epub 2018 Oct 14. J Cell Physiol. 2019. PMID: 30317611 Review.
143 results